Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
The activity of telavancin was evaluated against Staphylococcus spp. collected from European hospitals as part of an international surveillance study (2007-2008). A total of 7534 staphylococcal clinical isolates [5726 Staphylococcus aureus and 1808 coagulase-negative staphylococci (CoNS)] were included. Isolates were tested for susceptibility according to reference methods and minimum inhibitory concentration (MIC) values were interpreted based on Clinical and Laboratory Standards Institute (CLSI) 2010 and European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2009 criteria. Telavancin breakpoints approved by the US Food and Drug Administration (FDA) were applied. Telavancin activity was evaluated against meticillin-resistant S. aureus (MRSA) displaying several antibiogram resistance patterns, including multidrug-resistant isolates. Telavancin was active against S. aureus [MIC(50/90) values (MICs for 50% and 90% of the isolates, respectively)=0.12/0.25mg/L; 100.0% susceptible] and CoNS (MIC(50/90)=0.12/0.25mg/L), inhibiting all isolates at < or =0.5mg/L. Similar results were observed when S. aureus were stratified by year or country of origin (MIC(50/90)=0.12/0.25mg/L). When MRSA isolates were clustered according to 48 different resistance patterns, telavancin showed consistent MIC(90) values (0.25mg/L) regardless of multidrug resistance. Amongst CoNS, telavancin was slightly more active against Staphylococcus capitis, Staphylococcus epidermidis, Staphylococcus hominis, Staphylococcus lugdunensis and Staphylococcus xylosus (MIC(50)=0.12 mg/L) compared with Staphylococcus haemolyticus, Staphylococcus saprophyticus and Staphylococcus warneri (MIC(50)=0.25mg/L). Overall, telavancin exhibited MIC(90) results two- to eight-fold lower than comparators (daptomycin, quinupristin/dalfopristin, vancomycin and linezolid). Based upon MIC(90) values, telavancin demonstrated potent in vitro activity against a contemporary (2007-2008) collection of Staphylococcus spp. recovered from nearly 30 European medical centres.
Mendes
Rodrigo E
RE
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA. rodrigo-mendes@jmilabs.com
Sader
Helio S
HS
Jones
Ronald N
RN
D000617:Aminoglycosides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D003030:Coagulase / Q000378:metabolism; D024881:Drug Resistance, Bacterial; D005060:Europe / Q000453:epidemiology; D006760:Hospitalization; D006801:Humans; D000077427:Lipoglycopeptides; D008826:Microbial Sensitivity Tests / Q000592:standards; D011159:Population Surveillance; D013203:Staphylococcal Infections / Q000382:microbiology*; D013210:Staphylococcus / Q000145:classification / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D013211:Staphylococcus aureus / Q000187:drug effects / Q000201:enzymology / Q000302:isolation & purification
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D003030:Coagulase; D000077427:Lipoglycopeptides; C487637:telavancin